Laurus Labs board approves acquisition of 60% stake in Galenvs Sciences Inc.
(29 Oct 2026)

Back
The board of Laurus Labs at its meeting held on 29 October 2026 has approved for acquisition of 60% share capital of Galenvs Sciences Inc. (Galenvs), a Canada based company, at a pre-money valuation of USD 3.50 million. The company proposes to invest a total of USD 3.75 million, which includes primary infusion of USD 2.75 million and a secondary acquisition of USD 1.00 million.

Galenvs is a contract research and development organization (CRO/ CDMO) specializing in custom oligonucleotide synthesis and functional magnetic-nanoparticle (MNP) technologies for the diagnostics and therapeutics markets. It operates a vertically integrated platform spanning discovery, optimization, synthesis, purification, validation and pilot-scale production.

BSE Delayed data sourced at 5 mins : www.bseindia.com | NSE Delayed data sourced at 15 mins : www.nseindia.com

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew